Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells.
Roger SunNora SundahlMarkus HechtFlorian PutzAndrea LanciaAngela RouyarMarina MilicAlexandre CarréEnzo BattistellaEmilie Alvarez AndresStéphane NiyotekaEdouard RomanoGuillaume LouvelJérôme Durand-LabrunieSophie BockelRastilav BahledaCharlotte RobertCeline BoutrosMaria VakalopoulouNikos ParagiosBenjamin FreyJean-Charles SoriaChristophe MassardCharles FertéRainer FietkauPiet OstUdo S GaiplEric DeutschPublished in: Journal for immunotherapy of cancer (2021)
These results enhance the predictive value of the biologically inspired CD8 radiomics score and suggests that tumor heterogeneity should be systematically considered in patients treated with IORT. This CD8 radiomics signature may help select patients who are most likely to benefit from IORT.
Keyphrases
- end stage renal disease
- lymph node metastasis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- contrast enhanced
- induced apoptosis
- nk cells
- early stage
- radiation therapy
- peritoneal dialysis
- type diabetes
- prognostic factors
- squamous cell carcinoma
- magnetic resonance imaging
- single cell
- radiation induced
- metabolic syndrome
- rectal cancer